Abeona Therapeutics (ABEO) Competitors $5.48 +0.02 (+0.27%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ABEO vs. ZYME, DAWN, RCKT, PHVS, CDMO, COGT, OCS, PRTA, MRVI, and AVBPShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Zymeworks (ZYME), Day One Biopharmaceuticals (DAWN), Rocket Pharmaceuticals (RCKT), Pharvaris (PHVS), Avid Bioservices (CDMO), Cogent Biosciences (COGT), Oculis (OCS), Prothena (PRTA), Maravai LifeSciences (MRVI), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical preparations" industry. Abeona Therapeutics vs. Zymeworks Day One Biopharmaceuticals Rocket Pharmaceuticals Pharvaris Avid Bioservices Cogent Biosciences Oculis Prothena Maravai LifeSciences ArriVent BioPharma Zymeworks (NYSE:ZYME) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is ZYME or ABEO more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Abeona Therapeutics N/A -203.27%-64.56% Does the MarketBeat Community believe in ZYME or ABEO? Abeona Therapeutics received 230 more outperform votes than Zymeworks when rated by MarketBeat users. Likewise, 69.40% of users gave Abeona Therapeutics an outperform vote while only 67.74% of users gave Zymeworks an outperform vote. CompanyUnderperformOutperformZymeworksOutperform Votes29467.74% Underperform Votes14032.26% Abeona TherapeuticsOutperform Votes52469.40% Underperform Votes23130.60% Which has higher valuation and earnings, ZYME or ABEO? Abeona Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M10.92-$118.67M-$1.61-7.44Abeona Therapeutics$3.50M68.00-$54.19M-$2.69-2.04 Does the media refer more to ZYME or ABEO? In the previous week, Zymeworks had 21 more articles in the media than Abeona Therapeutics. MarketBeat recorded 27 mentions for Zymeworks and 6 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.43 beat Zymeworks' score of 0.26 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 3 Very Positive mention(s) 3 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Abeona Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ZYME or ABEO? Zymeworks currently has a consensus target price of $21.00, suggesting a potential upside of 75.29%. Abeona Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 219.63%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in ZYME or ABEO? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 1.9% of Zymeworks shares are held by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, ZYME or ABEO? Zymeworks has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. SummaryAbeona Therapeutics beats Zymeworks on 11 of the 19 factors compared between the two stocks. Remove Ads Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$237.79M$6.92B$5.62B$8.05BDividend YieldN/A2.71%4.89%4.04%P/E Ratio-2.036.1523.7718.95Price / Sales68.00224.11380.82116.93Price / CashN/A65.6738.0534.62Price / Book9.136.586.854.22Net Income-$54.19M$139.77M$3.19B$246.59M7 Day Performance4.09%-1.56%-2.32%-3.12%1 Month Performance-8.75%-6.78%-7.30%-9.01%1 Year Performance-33.07%-7.22%8.63%0.99% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics3.9621 of 5 stars$5.48+0.3%$17.50+219.6%-30.1%$237.79M$3.50M-2.03N/AUpcoming EarningsZYMEZymeworks3.0706 of 5 stars$12.74-4.9%$19.17+50.4%+5.9%$877.51M$62.20M-8.49460Analyst ForecastAnalyst RevisionNews CoverageDAWNDay One Biopharmaceuticals2.5112 of 5 stars$8.25-8.9%$34.86+322.5%-42.8%$836.18M$131.16M-8.0160High Trading VolumeRCKTRocket Pharmaceuticals4.5815 of 5 stars$8.79-7.0%$42.30+381.2%-70.3%$801.27MN/A-3.20240Analyst ForecastPHVSPharvaris1.7269 of 5 stars$15.32-3.6%$40.50+164.4%-31.9%$801.08MN/A-5.4730News CoverageCDMOAvid Bioservices0.9497 of 5 stars$12.50+0.1%$12.25-2.0%+92.2%$799.18M$139.91M-5.23320High Trading VolumeCOGTCogent Biosciences2.1384 of 5 stars$7.00-7.0%$14.00+100.0%+11.4%$796.95MN/A-2.8280OCSOculis1.6875 of 5 stars$19.54-0.2%$28.80+47.4%+58.2%$791.45M$980,000.00-10.122Earnings ReportUpcoming EarningsNews CoverageGap DownPRTAProthena3.1082 of 5 stars$14.33-9.4%$55.00+283.8%-51.0%$771.08M$135.16M-6.23130Positive NewsMRVIMaravai LifeSciences3.9077 of 5 stars$3.02-6.2%$9.28+207.3%-65.9%$762.64M$276.92M-1.84610AVBPArriVent BioPharma1.1403 of 5 stars$22.03-6.7%$38.00+72.5%+16.3%$742.35MN/A0.0040Analyst ForecastNews CoveragePositive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Zymeworks Alternatives Day One Biopharmaceuticals Alternatives Rocket Pharmaceuticals Alternatives Pharvaris Alternatives Avid Bioservices Alternatives Cogent Biosciences Alternatives Oculis Alternatives Prothena Alternatives Maravai LifeSciences Alternatives ArriVent BioPharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABEO) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | SponsoredElon Refuses to Pay a DividendElon Musk refuses to pay a Tesla dividend. But thanks to a new investment breakthrough… You could start ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
